SCHEMBL17217173

SCHEMBL17217173

Fc1ccc(/[C]=N\OCc2ccccc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAOB P27338 4/20 0.39
▸ TSHR P16473 1/20 0.38
▸ AR P10275 1/20 0.38
▸ IDO1 P14902 3/20 0.37
▸ AGXT P21549 2/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ PKM P14618 1/20 0.36
▸ APP P05067 1/20 0.35
▸ NR4A2 P43354 1/20 0.35
▸ PTGS1 P23219 1/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217175 1.00 KMT2A (0.40) KMT2AALDH1A1MEN1RECQLNPC1
SCHEMBL17218405 0.93 IDO1 (0.41) KMT2AALDH1A1MEN1RECQLNPC1
SCHEMBL17218407 0.93 IDO1 (0.41) KMT2AALDH1A1MEN1RECQLNPC1
SCHEMBL17219123 0.91 IDO1 (0.45) MAOBIDO1AGXTL3MBTL1APP
SCHEMBL17219126 0.91 IDO1 (0.45) MAOBIDO1AGXTL3MBTL1APP
SCHEMBL17217965 0.91 AGXT (0.42) NPC1RAB9ASMN1; SMN2GAAIDO1
SCHEMBL17217967 0.91 AGXT (0.42) NPC1RAB9ASMN1; SMN2GAAIDO1
SCHEMBL17219268 0.87 TSHR (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2GAA
SCHEMBL4196342 0.87 TSHR (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2GAA
SCHEMBL4196340 0.87 TSHR (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 KMT2A 2914/4885ALDH1A1 2300/4885MEN1 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback